Nuclear Import and Export Signals Enable Rapid Nucleocytoplasmic Shuttling of the Atypical Protein Kinase C lambda *

Maria PeranderDagger, Geir Bjørkøy, and Terje Johansen§

From the Biochemistry Department, Institute of Medical Biology, University of Tromsø, 9037 Tromsø, Norway

Received for publication, November 15, 2000, and in revised form, December 12, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The atypical protein kinase C (PKC) isoenzymes, lambda /iota - and zeta PKC, play important roles in cellular signaling pathways regulating proliferation, differentiation, and cell survival. By using green fluorescent protein (GFP) fusion proteins, we found that wild-type lambda PKC localized predominantly to the cytoplasm, whereas both a kinase-defective mutant and an activation loop mutant accumulated in the nucleus. We have mapped a functional nuclear localization signal (NLS) to the N-terminal part of the zinc finger domain of lambda PKC. Leptomycin B treatment induced rapid nuclear accumulation of GFP-lambda as well as endogenous lambda PKC suggesting the existence of a CRM1-dependent nuclear export signal (NES). Consequently, we identified a functional leucine-rich NES in the linker region between the zinc finger and the catalytic domain of lambda PKC. The presence of both the NLS and NES enables a continuous shuttling of lambda PKC between the cytoplasm and nucleus. Our results suggest that the exposure of the NLS in both lambda - and zeta PKC is regulated by intramolecular interactions between the N-terminal part, including the pseudosubstrate sequence, and the catalytic domain. Thus, either deletion of the N-terminal region, including the pseudosubstrate sequence, or a point mutation in this sequence leads to nuclear accumulation of lambda PKC. The ability of the two atypical PKC isoforms to enter the nucleus in HeLa cells upon leptomycin B treatment differs substantially. Although lambda PKC is able to enter the nucleus very rapidly, zeta PKC is much less efficiently imported into the nucleus. This difference can be explained by the different relative strengths of the NLS and NES in lambda PKC compared with zeta PKC.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The protein kinase C (PKC)1 family of lipid-dependent serine/threonine kinases plays pivotal roles in a wide variety of cellular processes (reviewed in Refs. 1-3). Based on sequence homology, domain organization, and biochemical properties, 10 different isoforms are grouped into three classes denoted classical, novel, and atypical PKCs. zeta PKC and lambda /iota PKC constitute the atypical PKCs (aPKCs). In contrast to the classical and novel PKCs that contain two repeated diacylglycerol (DAG)-binding zinc finger domains within their regulatory domains, the aPKCs have only a single zinc finger domain that is unable to interact with DAG or phorbol esters (4, 5). Consequently, they do not require DAG for their activation. Atypical PKCs have instead been shown to be regulated in vitro and in vivo by other lipid products such as ceramide (6, 7) and phosphatidylinositol 3,4,5-trisphosphate, a product of phosphatidylinositol 3-kinase (PI 3-kinase) (8-10). Consistently, aPKCs are strongly implicated as downstream effectors of PI 3-kinase (8, 10-14). Recently, evidence has accumulated that imply important roles for aPKCs in processes as diverse as proliferation (15, 16), differentiation (17-19), cell polarity (reviewed in Ref. 20), insulin-mediated up-regulation of general protein synthesis (21), glucose transport (22-24), up-regulation of alpha 2 integrin gene expression (25), and cell survival (26-30).

Interestingly, in addition to cytoplasmic proteins nuclear proteins also have been reported to act as substrates for aPKCs (31-33). The RNA-binding protein nucleolin is phosphorylated by zeta PKC in response to nerve growth factor (NGF) treatment of PC12 cells (33). Heterogeneous ribonucleoprotein-A1, another RNA-binding protein involved in splicing and mRNA transport, is also a substrate of zeta PKC (31). Both nucleolin and heterogeneous ribonucleoprotein-A1 shuttle between the cytoplasm and the nucleus. The ubiquitously expressed transcription factor Sp1 is able to form a complex with zeta PKC. In fact, zeta PKC phosphorylates Sp1 within the DNA-binding domain and stimulates Sp1-mediated transactivation of the vascular permeability factor/vascular endothelial growth factor promoter (32). Nuclear localization of both zeta - and lambda PKC has been demonstrated. NGF stimulation of PC12 cells led to rapid and transient translocation of zeta PKC from the cytoplasm to the nucleus (33-35). In resting HepG2 cells ectopically expressed lambda PKC was found both in the cytoplasm and in the nucleus (8). Upon stimulation with either platelet-derived growth factor or epidermal growth factor, the nuclear pool of lambda PKC translocated in a wortmannin-sensitive manner to the cytoplasm and to more compact structures within the nucleus.

Specific targeting of signaling protein kinases to subcellular compartments offers an important level of regulation in which the accessibility of their specific activators and substrates can be spatiotemporally limited. The presence of conserved nuclear localization signals (NLSs) allows rapid import to the cell nucleus via the formation of trimeric NLS-importin alpha -importin beta  complexes (36-40). During the last few years, short leucine-rich nuclear export signals (NESs) have been identified within a variety of proteins like human immunodeficiency virus-1 Rev (41), PKI (42), mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (43), mitogen-activated protein kinase-activated protein kinase-2 (MAPKAP-kinase 2) (44), cyclin B (45), and phospholipase C-delta 1 (46). NES-dependent nuclear export is inhibited by leptomycin B that interferes with the binding of NES to CRM1/exportin 1 (47-51).

Here we have studied the subcellular localization of lambda - and zeta PKC in living cells using green fluorescent protein (GFP) fusion proteins. We find that a kinase-defective mutant of lambda PKC accumulates in the cell nucleus, whereas the wild-type kinase is mainly cytosolic. Inhibition of CRM1-dependent nuclear export using leptomycin B leads to rapid nuclear accumulation of both GFP-lambda and endogenous lambda PKC. By deletion studies and site-directed mutagenesis, we identified both a functional NLS and an NES in lambda PKC. These signals endow lambda PKC with the ability to shuttle continuously between the cytoplasm and the nucleus. Our results are compatible with the notion that the exposure of the NLS in both lambda PKC and zeta PKC may be regulated by intramolecular interactions between the N-terminal region and the catalytic domain of the kinases. Also, we find that zeta PKC is much less efficiently imported into the nucleus than lambda PKC in HeLa cells upon blockade of nuclear export by leptomycin B treatment. This is most likely due to differences in the relative strengths of the NES and NLS in the two atypical PKCs.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Cell Cultures-- HeLa cells (ATCC CCL2) were grown in Eagle's minimum essential medium supplemented with 10% fetal calf serum, nonessential amino acids, 2 mM L-glutamine, penicillin (100 units/ml), and streptomycin (100 µg/ml) (Life Technologies, Inc). HEK293 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, and the antibiotics described above. Subconfluent HeLa and HEK293 cells were transfected using the calcium-phosphate coprecipitation method. For the nuclear export experiments, leptomycin B, kindly provided by Dr. M. Yoshida, Tokyo, was added to the medium to a final concentration of 2 ng/ml.

Plasmid Constructions and Site-directed Mutagenesis-- The murine lambda PKC cDNA was amplified from a mouse brain cDNA library (Marathon Ready, CLONTECH) by PCR using ExTaq polymerase (Takara Biomedicals). The PCR product was made blunt and subcloned into the SmaI site of pUC18. Inspection of the cDNA sequences show that both the murine lambda PKC and the human iota PKC cDNAs actually contain an in frame ATG codon nine codons upstream of the proposed start codon (5, 52). The Xenopus lambda PKC also contains this start codon eight amino acids upstream of the second ATG codon. Since this is the first in frame ATG and the amino acid sequences of this N-terminal extension also are conserved between the species, we suggest that this most 5' ATG is the start codon of lambda /iota PKC. Consequently, the numbering system used in this paper is based on this. To generate pHA-lambda , pUC18-lambda PKC was digested with EcoRI and XbaI, and the fragment containing the coding region for full-length lambda PKC (amino acids 1-595 in our numbering system) was inserted into the corresponding sites of pcDNA3-HA. pcDNA3-HA was a kind gift from Dr. Jorge Moscat and contains an influenza hemagglutinin (HA) epitope tag inserted into the HindIII-EcoRI sites of pcDNA3 (Invitrogen). pGFP-lambda was made from pHA-lambda by inserting the EcoRI-XbaI (blunted) fragment encoding lambda PKC into the EcoRI-SmaI sites of pEGFP-C1 vector (CLONTECH). pGFP-zeta was made from pHA-zeta (kindly provided by dr. Jorge Moscat) by inserting an EcoRI-XbaI (blunted) fragment encoding rat zeta PKC into the EcoRI-SmaI sites of pEGFP-C1. The expressions plasmids for HA-lambda K282W, GFP-lambda K282W, GFP-lambda T411A, GFP-lambda T411E, GFP-lambda K282W-R150E/R151E, GFP-lambda (141-162)R150E/R151E, GFP-lambda F253A/L255A, GFP-lambda A129E, GFP-zeta K281W, and GFP-zeta F252A/L254A were made by site-directed mutagenesis according to the instruction manual for the Quick-Change Site-directed Mutagenesis Kit (Stratagene) using the lambda PKCK282W, lambda PKCT411A, lambda PKCT411E, lambda PKCR150E/R151E, lambda PKCF253A/L255A, lambda PKCA129E, zeta PKCK281W, and zeta PKCF252A/L254A mutagenesis primers (Table I). The GFP-lambda and GFP-zeta deletion mutants were made using the following strategy. Different parts of the lambda - or zeta PKC cDNAs were amplified by PCR using primers that contained recognition sequences for specific restriction enzymes. The PCR products were purified and digested with restriction enzymes and inserted into the corresponding sites of pEGFP-C1. All constructs were verified by sequencing. All GFP-lambda /-zeta constructs are named according to the included parts of either lambda PKC or zeta PKC with the amino acid positions shown in parentheses. To study the localization of the regulatory domain of lambda PKC, two different constructs were made encoding fusion proteins where GFP was either fused to the N-terminal end or the C-terminal end. pUC18-reglambda was generated by PCR using pUC18-lambda PKC as template and the lambda PKCR.5pr and lambda 256.3nt primers (Table I). The PCR product was made blunt and subcloned into the SmaI site of pUC18. pUC18-reglambda was digested with NheI (blunted) and EcoRI, and the reglambda fragment was inserted into the ApaI (blunted) and EcoRI sites of pEGFP-N1 (CLONTECH). To make pGFP-lambda (1-256), preglambda -GFP was cut with EcoRI and BamHI, and the reglambda fragment was cloned into the corresponding sites of pEGFP-C1. pGFP-lambda (256-595) was made from a PCR product generated by using pUC18-lambda PKC as template and the primers lambda PKCcat.5pr and lambda PKC.3nt. The PCR product was cut with XbaI (blunted) and EcoRI and inserted into SmaI-EcoRI digested pEGFP-C1. pGFP-lambda (1-139) was constructed by inserting an EcoRI-MscI fragment from pGFP-lambda (1-256) into the EcoRI-SmaI sites of pEGFP-C1. pGFP-lambda (141-595) was made by PCR using the lambda PKC141.5pr and the lambda PKC.3nt primers. The product was cut with XbaI (blunted) and EcoRI and cloned into the EcoRI-SmaI sites of pEGFP-C1. pGFP-lambda (194-256) was constructed from a PCR product amplified using the lambda 194.5pr and lambda 256.3nt primers, digested with EcoRI and NheI (blunted), and inserted into the EcoRI-SmaI sites of pEGFP-C1. To make pGFP-lambda (141-194), the lambda 141.5pr and lambda 194.3nt primers were used, and the PCR product was cut with EcoRI and BamHI and inserted into the corresponding sites of pEGFP-C1. Exactly the same strategy was used to make pGFP-lambda (1-194) and pGFP-lambda ,(163-194) using the primers lambda PKCR.5pr and lambda PKC194.3nt for pGFP-lambda (1-194) and lambda PKC163.5pr and lambda PKC194.3nt for pGFP-lambda (163-194) (Table I). pGFP-lambda (141-163) was made from pGFP-lambda (141-194) by inserting an EcoRI-Eco0109I (blunted) fragment into EcoRI-SmaI-digested pEGFP-C1. To make pGFP-zeta (132-182) a cDNA fragment encoding the zinc finger domain of zeta PKC was amplified from mouse brain cDNA library using the mzeta PKC132.5pr and mzeta PKC182.3nt primers (Table I). The PCR product was cut with BamHI and EcoRI before being inserted into the corresponding sites of pEGFP-C1. To make pGFP-alpha (37-88) and pGFP-alpha (37-155), containing one or both of the zinc finger domains from murine alpha PKC fused to GFP, the same strategy as for construction of pGFP-zeta (132-182) was used except that the alpha PKC37.5pr and alpha PKC88.3nt primers were used for pGFP-alpha (37-88) and the alpha PKC37.5pr and alpha PKC155.3nt primers were used for pGFP-alpha (37-155). pGFP-zeta (255-592) and pGFP-zeta (130-592) were made from PCR products amplified using pHA-zeta PKC as template and the zeta cat.5pr and zeta PKC.3nt primers for pGFP-zeta (254-592) and primers zeta 130.5pr and zeta PKC.3nt for pGFP-zeta (130-592). The PCR products were blunted, cut with EcoRI, and cloned into the EcoRI-SmaI sites of pEGFP-C1. pGFP-zeta (1-255) was made from a PCR product generated using the zeta PKC.5pr and zeta PKC255.3nt primers that was cut with EcoRI and BamHI and inserted into the corresponding sites within pEGFP-C1. pGFP-zeta (1-182) and pGFP-zeta (130-255) were generated following exactly the same strategy as for pGFP-zeta (1-255) using the zeta PKC5.pr and zeta PKC182.3nt primers for pGFPzeta (1-182) and the primers zeta PKC130.5pr and zeta PKC255.3nt for pGFP-zeta (130-255).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Sequences of oligonucleotides used as PCR primers for plasmid constructions and site-directed mutagenesis

Subcellular Localization Analyses and Immunocytochemistry-- For the subcellular localization studies of the different GFP fusion proteins, HeLa cells were seeded in 6-well dishes at a density of 5 × 104 cells per well 24 h before transfection. The cells were transfected with 1 µg of expression vectors for the different GFP fusions. The subcellular localizations of the GFP fusion proteins in living cells were visualized by fluorescence microscopy using a Leitz DMIRB invert microscope equipped for fluorescence and with a Leica DC100 digital camera. For DAPI staining the cells were fixed and permeabilized in 4% paraformaldehyde, 0.01% Triton X-100 for 10 min at 4 °C, and the DNA was stained with 1 µg/ml DAPI (Sigma) for 5 min at room temperature. HA-lambda and HA-lambda K282W were detected using a monoclonal anti-HA antibody (12CA5, Roche Molecular Biochemicals). Subconfluent HEK293 cells in 24-well culture dishes were cotransfected with 0.4 µg of the different GFP-lambda /-zeta -expressing plasmids and 0.4 µg of vectors expressing either HA-lambda or HA-lambda K282W. Twenty four h later the cells were fixed by adding freshly made paraformaldehyde directly to medium to a final concentration of 4%. The cells were permeabilized for 10 min on ice using methanol pre-chilled at -20 °C. The aldehyde groups were quenched by incubating the cells with 10 mM glycine, pH 8.5, for 5 min at room temperature. The fixed cells were incubated with 3% pre-immune goat serum in phosphate-buffered saline for 1 h at room temperature before incubation with the anti-HA antibody diluted 1:500 in blocking solution for 1 h at room temperature or overnight at 4 °C. The immunostaining was developed using an Alexa 594-conjugated goat anti-mouse IgG secondary antibody (Molecular Probes) diluted 1:500 in blocking solution. Endogenous lambda PKC in HeLa cells was detected by staining with an anti-lambda PKC antibody (clone 41, Transduction Laboratories) at a dilution of 1:200.

Preparation of Cytosolic/Nuclear Extracts and Immune Complex Kinase Assays-- The activities of the different GFP-lambda /-zeta mutants and HA-lambda /-zeta were measured in total cellular extracts by immune complex kinase assays using histone H1 as substrate. Subconfluent cultures of HeLa cells in 100-mm diameter Petri dishes were transfected with 10 µg of vectors expressing the different GFP-lambda /-zeta mutants or HA-lambda /-zeta . The cells were harvested by trypsinization 24 h post-transfection, and nuclear extracts were prepared as described (53). All buffers contained 1 tablet per 10 ml of Complete Mini, EDTA-free protease inhibitor mixture (Roche Molecular Biochemicals), 1 mM sodium vanadate, and 10 mM beta -glycerophosphate. Following isolation of the nuclei by centrifugation, the supernatant containing the cytosolic extract was removed. Finally, the cytosolic and nuclear extracts were mixed to give total cellular extracts. Approximately equal amounts of the different GFP- or HA-tagged proteins were immunoprecipitated from total cell extracts as follows. Total cellular extracts from 100-mm culture dishes were preincubated with unsaturated 50% gel-slurry solution of protein A-Sepharose CL-4B beads (Amersham Pharmacia Biotech) for 20 min at 4 °C and then incubated for 2 h at 4 °C with either 1 µg of anti-HA antibody (12CA5, Roche Molecular Biochemicals) or 2 µg of polyclonal anti-GFP antibody (Molecular Probes) in a total volume of 400 µl in HA lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM EGTA, 1% Triton X-100). Fifteen µl of bovine serum albumin-saturated 50% gel-slurry was added to the samples before continuing the incubation for 1 h at 4 °C. The samples were washed five times in HA lysis buffer and once in lambda /zeta -kinase buffer (35 mM Tris-HCl, pH 7.5, 10 mM MgCl2, 0.5 mM EGTA, 0.1 mM CaCl2). The complexes were resuspended in 15 µl of kinase buffer containing 3 µg of histone H1 (Calbiochem), 60 µM ATP, and 2 µCi of [gamma -32P]ATP and incubated at 30 °C for 20 min. The kinase reactions were terminated by adding 3.8 µl of 5× SDS-polyacrylamide gel electrophoresis load buffer, and the samples were boiled immediately for 5 min. The samples were run on a 10% polyacrylamide gel and electrotransferred to a nitrocellulose membrane (Hybond ECL, Amersham Pharmacia Biotech). The phosphorylated proteins were detected and quantitated using a PhosphorImager (Molecular Dynamics). The amount of immunoprecipitated GFP-lambda /-zeta and HA-lambda was determined by probing the membrane with the specific anti-lambda PKC antibody or an anti-zeta PKC antibody (Upstate Biotechnology) that recognizes both zeta PKC and lambda PKC. The chemiluminescence signals from the blots were detected using a LumiImager F1 (Roche Molecular Biochemicals) and quantitated as Boehringer light units using the LumiAnalyst 3.0 software. The relative activities of GFP-lambda and HA-lambda were determined as PhosphorImager units of phosphorylated substrate divided on the Boehringer light units representing the amount of kinase used.

Western Blot Analyses-- HeLa cells were seeded at 4 × 105 per 100-mm dish the day before transfection. The cells were transfected with 10 µg of the different GFP-lambda /-zeta expression vectors. Twenty four h post-transfection the cells were scraped directly in 100 µl of 2× SDS-polyacrylamide gel electrophoresis gel load buffer, boiled for 5 min, and sonicated briefly. The samples were run on 10% SDS-polyacrylamide gels and blotted onto Hybond nitrocellulose membranes. The membranes were blocked in 5% nonfat dry milk in TBST (10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% Tween 20) for 1 h at room temperature and then incubated with the primary antibody diluted in TBST for 1 h at room temperature or overnight at 4 °C. The following primary antibodies were used: anti-GFP, polyclonal (diluted 1:2000, CLONTECH), anti-lambda PKC (0.1 µg/ml, clone 41, Transduction Laboratories), anti-zeta PKC (0.5 µg/ml, Upstate Biotechnology, Inc.), and anti-HA (1 µg/ml, 12CA5, Roche Molecular Biochemicals). The membranes were washed 6 times in TBST and incubated with horseradish peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG secondary antibodies (0.2 µg/ml, Transduction Laboratories) for 1 h at room temperature. The washing step described above was repeated, and the membranes were developed using the ECL system following the instructions of the manufacturer (Amersham Pharmacia Biotech).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Different Subcellular Localization of Wild-type lambda PKC and Two Mutants with Single Mutations in the Catalytic Domain-- Vectors for expression of murine lambda PKC with either an HA epitope tag or enhanced green fluorescent protein (GFP) fused to its N terminus were constructed. The expressed proteins were denoted HA-lambda and GFP-lambda , respectively. A point mutation was introduced into the ATP-binding site to generate a kinase-defective mutant of lambda PKC, lambda K282W. To test if the relatively large GFP moiety affected the kinase activity of lambda PKC, immune complex kinase assays were performed to compare the ability of HA-lambda and GFP-lambda to phosphorylate histone H1. As shown in Fig. 1, HA-lambda and GFP-lambda immunoprecipitated from transiently transfected HeLa cells showed similar activities with GFP-lambda even being a bit more active than HA-lambda . The GFP fusion to the ATP-binding site mutant (GFP-lambda K282W) showed no activity as expected. This strongly suggests that the fusion of GFP to the N-terminal of lambda PKC has no significant effect on kinase activity.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 1.   The kinase activity of lambda PKC is not affected by the GFP fusion partner. Subconfluent HeLa cells in 100-mm dishes were transfected with 10 µg of either pEGFP-C1 vector or expression constructs for GFP-lambda , GFP-lambda K282W, or HA-lambda . Twenty four h after transfection, whole cell extracts were made by mixing nuclear and cytosolic extracts as described under "Materials and Methods." GFP, GFP-lambda , GFP-lambda K282W, or HA-lambda were immunoprecipitated (IP) using an anti-GFP antibody or an anti-HA antibody, and their kinase activities were determined using histone H1 as substrate. Protein loading was determined by immunoblotting (WB) with an antibody against lambda PKC. The relative activities represent the amount of substrate phosphorylated and quantitated using a PhosphorImager divided on the amount of kinase protein used in the assays quantitated by means of a LumiImager.

To determine the subcellular localization of lambda PKC in living cells, HEK293 and HeLa cells transiently transfected with vectors expressing either GFP-lambda , GFP-lambda K282W, or GFP alone were analyzed by fluorescence microscopy. GFP-lambda was mainly localized to the cytoplasm in both cell lines although a fraction of the protein was detected in the nucleus (Fig. 2A). Surprisingly, the GFP-lambda K282W mutant was localized to the cell nucleus in both cell types. The GFP protein alone was distributed diffusely throughout both the cytoplasm and the nucleus. To see if HA-tagged lambda  or lambda K282W displayed the same subcellular localization as their GFP counterparts, HEK293 cells were cotransfected with GFP-lambda and HA-lambda K282W or GFP-lambda K282W and HA-lambda . The subcellular localization of HA-lambda and HA-lambda K282W was determined in fixed cells by immunocytochemistry using an anti-HA monoclonal antibody. As shown in Fig. 2B, HA-lambda was localized predominantly to the cytoplasm, whereas HA-lambda K282W accumulated in the nucleus. The nuclear localization of GFP-lambda K282W was also verified by confocal laser microscopy of transiently transfected NIH 3T3 cells (data not shown). Western blot analyses of whole cell extracts and immunostaining with a monoclonal antibody recognizing specifically the C-terminal catalytic domain of lambda PKC showed that the nuclear staining was due to full-length protein and not caused by a proteolytic fragment containing GFP and only part of lambda PKC (data not shown).


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 2.   Different subcellular localization of wild-type lambda PKC and two mutants with no or reduced activity. A, subcellular distribution of GFP-lambda and kinase-defective GFP-lambda K282W in HeLa and HEK293 cells. Subconfluent cultures of HeLa (upper panel) or HEK293 (lower panel) cells seeded in 6-well dishes were transfected with 1 µg of vectors expressing either GFP alone, GFP-lambda , or GFP-lambda K282W. The subcellular localization in living cells was visualized by fluorescence microscopy. HEK293 cells expressing GFP-lambda K282W were stained with DAPI to visualize the nuclei. The nuclei of HeLa and HEK293 cells expressing GFP-lambda K282W are indicated by arrows. B, similar subcellular distribution of HA-tagged (red) and GFP-tagged versions of wild-type and kinase-defective lambda PKC. HEK293 cells were seeded in 24-well dishes and cotransfected with expression vectors (0.4 µg) for HA-lambda and GFP-lambda K282W (upper panel) or HA-lambda K282W and GFP-lambda (lower panel). Twenty four h after transfection the cells were fixed and stained with an anti-HA antibody and analyzed by fluorescent microscopy. Arrows indicate the nuclei of coexpressing cells. C, kinase activity of different GFP-lambda mutants. Whole cell extracts from transiently transfected HeLa cells expressing either GFP alone, GFP-lambda , GFP-lambda K282W, GFP-lambda T411E, or GFP-lambda T411A were subjected to immunoprecipitation (IP) using an anti-GFP antibody. The kinase activities were determined using histone H1 as substrate. Autophosphorylation of immunoprecipitated proteins are indicated (32P-GFP-lambda ). The loading of immunoprecipitated proteins was visualized by immunoblotting with an antibody cross-reacting with both zeta - and lambda PKC. D, subcellular localization of GFP-lambda T411E and GFP-lambda T411A in transiently transfected HeLa cells.

Phosphorylation of a conserved threonine residue within the activation loop of all PKCs is crucial for subsequent autophosphorylation and activation of the enzyme (54). Substitution of this threonine in zeta PKC (Thr-410) with an acidic amino acid created a constitutively activated kinase, whereas replacing it with alanine severely reduced the catalytic activity (13, 55). To test if mutation of the corresponding Thr-411 site in lambda PKC affected the subcellular localization of the kinase, GFP fusion proteins containing alanine (GFP-lambda T411A) or glutamate (GFP-lambda T411E) substitutions at this site were expressed in HeLa cells. The catalytic activity of the T411A mutant was significantly reduced compared with wild-type lambda PKC and the T411E mutant (Fig. 2C). Interestingly, similar to the kinase-defective ATP-binding site mutant, GFP-lambda T411A was mainly nuclear in living HeLa cells, whereas GFP-lambda T411E displayed a predominantly cytosolic localization just as the wild-type lambda PKC (Fig. 2D). Taken together, these results indicate that the ATP-binding site and the T411A mutations may somehow affect the overall conformation of the protein so that signals governing subcellular localization are exposed differently in these mutants compared with the wild-type enzyme. However, as demonstrated below the observed nuclear accumulation is not correlated to the activity status of the kinase.

The Zinc Finger Domain of lambda PKC Contains a Nuclear Localization Signal-- Proteins larger than about 40-60 kDa cannot enter into the nucleus through the nuclear pore complex by passive diffusion (38, 39). Since both HA-lambda K282W (67 kDa) and GFP-lambda K282W (92 kDa) are too large to diffuse into the nucleus, it seemed logical to assume that lambda PKC could contain a functional nuclear localization signal (NLS) or be transported via interaction with a partner protein containing an NLS. Thus, to map the region(s) of lambda PKC required for nuclear localization, deletion mutants were made in the context of GFP fusion proteins (Fig. 3A). Plasmids expressing the different deletions were transfected into HeLa cells, and the expression of GFP fusion proteins with correct sizes was verified by Western blot analyses using an anti-GFP antibody (Fig. 3B). Fluorescence microscopy of living cells revealed that GFP-lambda (256-595) corresponding to the catalytic domain of lambda PKC was mainly localized diffusely in the cytoplasm (Fig. 3C). Due to a low level of expression of this construct in HeLa cells, GFP-lambda (256-595) was also transiently expressed in HEK293 cells. Compared with the distribution in HeLa cells, GFP-lambda (256-595) was even more excluded from the nucleus in HEK293 cells. In contrast, a fusion protein containing the regulatory domain, GFP-lambda (1-256) was primarily localized to the cell nucleus. We next analyzed which part of the regulatory domain that was responsible for the observed nuclear accumulation (Fig. 3C). GFP-lambda (1-139), containing the first 139 amino acids of lambda PKC including the pseudosubstrate sequence, was diffusely localized throughout the cell. The molecular mass of this construct is ~42 kDa so the protein will probably enter the nucleus by passive diffusion (38, 39). In contrast, a GFP fusion protein corresponding to the zinc finger domain of lambda PKC, GFP-lambda (141-194), was exclusively localized to the nucleus. This fusion protein further accumulated in structures corresponding to the nucleoli. These observations clearly suggest that the zinc finger domain contains a functional NLS. Surprisingly, GFP-lambda (194-256), containing the variable linker region between the zinc finger domain and the ATP-binding site, was excluded from the nucleus. According to the theoretical size of this fusion protein (about 35 kDa) one would expect that it could enter the nucleus by diffusion. Therefore, this fusion protein may be sequestered in the cytoplasm by an anchoring protein, or it may be actively exported from the nucleus.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 3.   Expression and subcellular localization of GFP fusion proteins containing different parts of the lambda PKC protein. A, schematic representation of different GFP-lambda constructs. The numbers in parentheses refer to amino acid positions defining the parts of the lambda PKC protein included in the fusions. B, immunoblotting of GFP-lambda deletion mutants. HEK293 cells were transfected with either pEGFP-C1 or 10 µg of expression vectors for either GFP-lambda , GFPlambda (256-595), GFPlambda (1-256), GFPlambda (1-139), GFPlambda (141-194), or GFPlambda (194-256). The cells were harvested 24 h post-transfection, and total cellular proteins were separated in 10% SDS-polyacrylamide gels. The proteins were electrotransferred to a membrane that was subsequently probed with an anti-GFP antibody. C, subcellular localization of the indicated GFPlambda deletion mutants.

The sequence identities between the zinc finger domain of lambda PKC and those of classical and novel PKCs vary from 35 to 48%, whereas there is 74% identity between the zinc finger domains of lambda PKC and zeta PKC (Fig. 4A). We therefore asked whether the zinc finger domain of zeta PKC, like that of lambda PKC, was able to direct a GFP fusion protein to the nucleus. To this end, HeLa cells were transfected with a construct expressing a GFP fusion protein containing the complete zinc finger domain of murine zeta PKC, GFP-zeta (130-182). Indistinguishable from the results with the corresponding lambda PKC construct, this fusion protein was exclusively nuclear demonstrating that the zinc finger domain of zeta PKC also contains an NLS (Fig. 4C). However, GFP fusion proteins containing either the first or both zinc finger domains of the classical isoform alpha PKC, GFP-alpha (37-88), and GFP-alpha (37-155) did not accumulate in the cell nuclei but rather in punctate structures in the cytoplasm (Fig. 4C). Thus, the ability to translocate to the nucleus is not a conserved feature of PKC zinc finger domains.


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 4.   The zinc finger region of atypical PKCs contain a nuclear localization signal. A, alignments of amino acid sequences of the zinc finger domains of murine lambda PKC (SwissProt accession number Q62074), rat zeta PKC (P09217), PKC3 from C. elegans (GenBankTM accession number AF025666), murine delta PKC (P28867), and murine alpha PKC (P20444). The sequences of both zinc finger domains of alpha PKC are shown with alpha PKC-1 as the most N-terminal zinc finger. Asterisks above the alignment denote the basic residues in the putative core NLS. The location of the two Arg residues mutated to Glu is indicated (EE). Conserved positions are indicated below the alignment (b, basic; h, hydrophobic; and a, aromatic). B, a three-dimensional structure model of the zinc finger domain of murine lambda PKC is shown to the right with the Arg-150 and Arg-151 residues indicated. The side chains of other Arg and Lys residues are also shown (blue). The model was obtained from the Swiss Model Repository. The x-ray structure model of the second zinc finger of delta PKC with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (in space-filling mode) bound and the two zinc atoms is shown to the left (77). C, subcellular localization of GFP fusions containing zinc finger regions of zeta PKC and alpha PKC. Constructs encoding GFP-zeta (130-182) containing the zinc finger region of murine zeta PKC, GFP-alpha (37-88) containing the first zinc finger of alpha PKC, and GFP-alpha (37-155) containing both zinc fingers of alpha PKC were expressed in HeLa cells. D, mutation of Arg-150 and Arg-151 within the zinc finger of lambda PKC prevents nuclear accumulation of kinase-defective lambda PKC. The subcellular localization of GFP-lambda K282W and GFP-lambda K282W-R150E/R151E in which Arg-150 and Arg-151 are replaced by glutamate residues was analyzed in HeLa cells. E, GFP-lambda (141-162) containing the first 22 amino acids of the lambda PKC zinc finger accumulates in the nucleus, whereas the NLS mutant GFP-lambda (141)-R150E/R151E is diffusely localized throughout the cell.

The zinc finger domain of the aPKCs does not contain classical monopartite or bipartite NLSs. However, lambda PKC, zeta PKC, and PKC3 from Caenorhabditis elegans contain a cluster of four basic amino acids in the N-terminal part of the zinc finger (KRF/LNRR in Fig. 4A). This motif is not found in the classical and novel PKCs as exemplified by the second zinc finger of delta PKC and both zinc fingers of alpha PKC in Fig. 4A. In a three-dimensional structure model of the zinc finger domain of lambda PKC, constructed based on the solved structure of the corresponding zinc finger of delta PKC, these basic residues are exposed on the surface. Particularly, Arg-150 and Arg-151 are ideally positioned to interact with either lipid cofactors or other proteins (Fig. 4B). To see if introduction of two acidic amino acids in this sequence could interfere with the nuclear localization of kinase-defective lambda PKC, Arg-150 and Arg-151 were substituted with glutamate residues giving GFP-lambda K282W-R150E/R151E. Interestingly, these mutations abolished the nuclear accumulation of kinase-defective GFP-lambda K282W. GFP-lambda K282W-R150E/R151E was either diffusely distributed throughout the cells or totally excluded from the nucleus (Fig. 4D). Thus, Arg-150 and Arg-151 seem to be critically involved in nuclear localization of lambda PKC. To see if the N-terminal half of the lambda PKC zinc finger, including the critical arginine residues, was sufficient for mediating nuclear translocation, GFP-lambda (141-162) encoding a GFP fusion protein containing the first 22 amino acids of the zinc finger was made. GFP-lambda (141-162) accumulated in the nuclei of transiently transfected HeLa cells (Fig. 4E). In contrast to the GFP fusion protein containing the complete zinc finger, GFP-lambda (141-162) did not accumulate in the nucleoli. Next, we mutated Arg-150 and Arg-151 in the context of the GFP-lambda (141-162) protein. GFP-lambda (141-162)R150E/R151E displayed the same diffuse subcellular distribution as GFP itself (Fig. 4E). Thus, our results strongly suggest that lambda PKC contains a functional NLS within the first 22 amino acids of the zinc finger domain and that Arg-150 and Arg-151 are critical residues within this NLS.

Leptomycin B Treatment Induces Nuclear Accumulation of lambda PKC-- To determine whether the predominantly cytoplasmic localization of wild-type lambda PKC is caused by the presence of a leucine-rich NES, GFP-lambda -transfected HeLa cells were treated with leptomycin B (LMB). Interestingly, treatment with LMB for 2 h induced nuclear accumulation of the fusion protein (Fig. 5A). To determine whether LMB could induce nuclear accumulation of endogenous lambda PKC, HeLa cells were either left untreated or treated with LMB for 2 h. The cells were fixed and the subcellular localization of endogenous lambda PKC was determined by immunocytochemistry using a specific anti-lambda PKC antibody. In untreated cells lambda PKC was diffusely localized mainly in the cytoplasm with only a fraction of the protein in the nucleus (Fig. 5B, left panel). Importantly, LMB treatment induced redistribution of endogenous lambda PKC from the cytoplasm to the nucleus (Fig. 5B, right panel). The nuclear accumulation of endogenous lambda PKC in response to LMB was rapid, being significant after 15 min and almost completed after 30 min (Fig. 5C). These results demonstrate that lambda PKC is exported from the nucleus by a mechanism either involving a functional cis-acting, LMB-sensitive NES or via an NES-containing interaction partner.


View larger version (75K):
[in this window]
[in a new window]
 
Fig. 5.   LMB induces nuclear accumulation of GFP-lambda and endogenous lambda PKC. A, HeLa cells were transfected with expression vector for GFP-lambda as described in the legend to Fig. 3A. Twenty four h after transfection, cells were either left untreated or treated with 2 ng/ml LMB for 2 h, and the subcellular localization of GFP-lambda was determined. B, HeLa cells were cultured in Eagle's minimum essential medium supplemented with 10% fetal calf serum and either left untreated or treated with LMB (2 ng/ml) for 2 h. The cells were fixed, permeabilized, and stained with an anti-lambda PKC antibody that shows no cross-reactivity against zeta PKC. C, an experiment performed similarly as in B except that LMB treatment was for 0-, 15- and 30 min, respectively.

Characterization of an NES within lambda PKC-- Since GFP-lambda (194-256), despite of its small size, was completely excluded from the nucleus (see Fig. 3C), we speculated that this part of lambda PKC, corresponding to the linker region between the zinc finger domain and the ATP-binding site, could be involved in active export from the nucleus. Interestingly, we identified a region (amino acids 248-255) that displayed significant similarity to previously identified NES sequences (Fig. 6A). To determine whether this region mediates nuclear export of lambda PKC, we generated a mutant of lambda PKC in which two presumably critical hydrophobic amino acids, Phe-253 and Leu-255, are replaced by alanine residues. Similar mutations within NES sequences in other proteins abolish the function of the NES (41-43, 45, 46). In contrast to the wild-type kinase, GFP-lambda F253A/L255A accumulated in the nucleus (Fig. 6B). This strongly suggests that cytoplasmic localization of lambda PKC is conferred by an NES in the linker region between the regulatory and the catalytic domains.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 6.   Characterization of an NES within the linker region of lambda PKC. A, alignments of NES sequences from mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (43), PKI (42), Rev (41)(18), PLCdelta 1 (46), and the atypical PKCs. Important hydrophobic residues are boxed. B, mutation of critical hydrophobic residues within the NES (Phe-253 and Leu-255) blocks nuclear export of lambda PKC. HeLa cells were transiently transfected with expression vectors for GFP-lambda or for GFP-lambda F253A/L255A, and the subcellular localization was determined 24 h after transfection.

Intramolecular Interactions between the N-terminal Pseudosubstrate Sequence and the Catalytic Domain Inhibit Nuclear Localization of lambda PKC-- To begin unraveling whether intramolecular interactions between the N-terminal part and the catalytic domain might mask the NLS in lambda PKC, a GFP-lambda fusion protein in which the first 140 amino acids were deleted was transiently expressed in HeLa cells. Contrary to the full-length, wild-type kinase, GFP-lambda (141-595) localized exclusively to the nucleus (Fig. 7). Since this fusion protein lacks the autoinhibitory pseudosubstrate sequence, the kinase activity of GFP-lambda (141-595) was increased compared with the wild-type enzymes (data not shown). To determine whether disruption of the intramolecular interaction between the pseudosubstrate sequence and the catalytic domain led to nuclear localization, a point mutant of GFP-lambda in which Ala-129 within the pseudosubstrate sequence was replaced by glutamate, GFP-lambda A129E, was generated and transiently expressed in HeLa cells. Such a mutant has previously been demonstrated to be constitutively activated presumably due to the lack of interaction of the pseudosubstrate sequence with the substrate interaction site in the catalytic domain (56). Consistent with the notion of a conformational change exposing the NLS, GFP-lambda A129E displayed nuclear accumulation (Fig. 7). Taken together, these results and those presented earlier indicate that it is not the activity status of the kinase as such that determines the subcellular localization. Instead, intramolecular interactions between the catalytic domain and the pseudosubstrate sequence inhibit the nuclear localization of lambda PKC by inducing a conformation where the NLS is masked.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 7.   Intramolecular interactions between the N-terminal pseudosubstrate sequence and the catalytic domain inhibit nuclear localization of lambda PKC. HeLa cells were transfected with the indicated GFP-lambda fusion constructs, and the subcellular localization was determined 24 h following transfection.

Nuclear Import of zeta PKC Is Much Less Efficient Than That of lambda PKC in LMB-treated HeLa Cells-- The aPKC subtypes, lambda PKC and zeta PKC, have the same structural organization and display considerable sequence homology especially within their catalytic domains. To establish if zeta PKC was similarly distributed within the cell as lambda PKC, we made a vector expressing GFP fused to full-length zeta PKC, pGFP-zeta . GFP-zeta was exclusively localized to the cytoplasm in untreated cells. Surprisingly, GFP-zeta did not accumulate in the nucleus upon LMB treatment for 2 h but was distributed diffusely all over the cell (Fig. 8A). However, after long term treatment with LMB (16 h), GFP-zeta accumulated in the nuclei of the transfected cells (data not shown). Since we did not have antibodies available that will only recognize zeta PKC specifically, without detecting lambda PKC, we were not able to analyze the subcellular distribution of endogenous zeta PKC by immunocytochemistry. To test whether kinase-defective zeta PKC localized differently from wild-type zeta PKC, GFP-zeta K281W mutated in the ATP-binding site was expressed in HeLa cells. Contrary to kinase-defective lambda PKC, GFP-zeta K281W was predominantly localized in the cytoplasm in a manner similar to wild-type GFP-zeta (Fig. 8C). Kinase assays performed following immunoprecipitation of GFP-zeta or GFP-zeta K281W from extracts of transiently transfected HeLa cells showed that GFP-zeta was active, whereas GFP-zeta K281W had no intrinsic kinase activity (Fig. 8C). Similar to GFP-lambda , GFP-zeta was as active as an HA epitope-tagged zeta PKC (data not shown). Next, we mutated the putative NES sequence in GFP-zeta generating GFP-zeta F252A/L254A. Compared with wild-type GFP-zeta , this construct distributed more diffusely all over the cells in transiently transfected HeLa cells but in contrast to GFP-lambda F253A/L255A, GFP-zeta F252A/L254A did not accumulate in the nucleus (data not shown). Taken together these results indicate that the nuclear import of zeta PKC is much less efficient than that of lambda PKC. To sort out if this is due to intrinsic differences in the relative strength/exposure of the NLS and NES in the two kinases, several GFP-zeta deletion mutants were made, and their subcellular distribution was compared with the distribution of corresponding GFP-lambda mutants. Very interestingly, GFP-zeta (130-592) that lacks the first 129 amino acids of zeta PKC, including the pseudosubstrate sequence, displayed the complete opposite localization compared with the corresponding GFP-lambda (141-595) being entirely excluded from the nucleus (Fig. 8D). However, LMB treatment induced rapid nuclear accumulation of this construct. Fig. 9 gives an overview of the subcellular localization of various GFP-lambda and -zeta mutants before and after LMB treatment. Our observations indicate that in zeta PKC the NES is a stronger signal than the NLS, and nuclear localization is only observed when the NES motif is removed or functionally inhibited. In contrast, in lambda PKC the NLS is more potent than the NES when both signals are exposed, and the nuclear import of lambda PKC is much more efficient than that of zeta PKC.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 8.   GFP-zeta does not accumulate in the nucleus following a 2-h treatment with LMB. A, HeLa cells were seeded in 6-well dishes, and subconfluent cells were transfected with 1 µg of a GFP construct containing wild-type rat zeta PKC. Twenty four h later the subcellular distribution of GFP-zeta was analyzed by fluorescence microscopy in cells which were either left untreated or treated with LMB (2 ng/ml) for 2 h. B, a kinase-defective mutant of zeta PKC does not accumulate in the nucleus upon expression in HeLa cells. GFP-zeta and GFP-zeta K281W, which contain an inactivating mutation in the ATP-binding site, were expressed in HeLa cells. The subcellular localization was determined 24 h post-transfection. C, kinase activity of GFP-zeta and GFP-zeta K281W. HeLa cells were seeded in 100-mm dishes the day before transfection, and subconfluent cultures were transfected with 10 µg of either an expression vector for GFP-zeta or an expression vector for GFP-zeta K281W. Cells were harvested 24 h after transfection, and the kinase activities of GFP-zeta and GFP-zeta K281W were assayed. Autophosphorylation of immunoprecipitated (IP) GFP-zeta is indicated. A Western blot (WB) of the immunoprecipitated proteins used in the kinase assays is also shown. D, deletion of the N-terminal regulatory domain containing the pseudosubstrate sequence of zeta PKC does not cause nuclear accumulation in the absence of LMB (2 ng/ml for 2 h).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 9.   Summary of subcellular localizations of GFP fusion proteins containing full-length or different parts of lambda - or zeta PKC before and after LMB treatment. HeLa cells in 6-well dishes were transfected with 1 µg of expression vector for each indicated GFP fusion protein and left untreated or treated with LMB (2 ng/ml) for 2 h at 24 h post-transfection before being analyzed by fluorescence microscopy. The locations of the NLS and NES motifs are shown (open diamond and triangle, respectively). C, cytoplasm; N, nucleus; C+N, both cytoplasm and nucleus; nd, not determined.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Nuclear localization of classical and novel PKCs as well as aPKCs has been observed previously (8, 35, 58-64). However, to our knowledge, this is the first report where functional NLS and NES sequences are identified within any PKC. We find that lambda PKC shuttles very rapidly and continuously between the nucleus and the cytoplasm. This rapid nucleocytoplasmic shuttling occurs both in noncycling serum-starved cells and in cycling cells proliferating in serum.

Our results suggest that the core of the NLS of lambda PKC consists of the hexapeptide KRFNRR located in the N-terminal part of the zinc finger domain (amino acids 146-151). This basic cluster is conserved in aPKCs from different species as well as in C. elegans PKC3 (KRLNRR) but not in classical and novel PKCs (Fig. 4A). An exception is provided by murine zeta PKC which contains a Gly residue instead of an Arg (KRFNGR), whereas the rat sequence contains the Arg. GFP fusion proteins containing the zinc finger region of either lambda PKC or zeta PKC (both rat and murine) localize exclusively to the nucleus. In contrast, GFP fusion constructs expressing either one or both zinc fingers of classical alpha PKC are excluded from the nucleus and rather distributed into punctate structures in the cytoplasm. A recent report (65) demonstrated that GFP fusion constructs that expressed only one or both of the zinc fingers of gamma PKC localized to the cytoplasm of rat basophilic leukemia cells. Upon treatment with various stimuli including phorbol esters, the zinc finger region of gamma PKC translocated to the plasma membrane. Thus, although evident for the aPKCs, nuclear localization is not a conserved feature of PKC zinc fingers as such.

Based on sequence analyses it has been suggested that both the classical and the aPKCs may contain a bipartite NLS (35). For lambda PKC this NLS would encompass two basic amino acids in the pseudosubstrate sequence (Arg-133 and Lys-134) and Arg-150 and Arg-151 in the motif identified by us (KRFNRR) in the zinc finger domain. Two such basic clusters within a bipartite NLS are interdependent on each other to mediate nuclear localization (36). The GFP construct containing the zinc finger region lacks the upstream basic cluster in this suggested bipartite NLS. Since this construct is exclusively localized to the cell nucleus, we do not think that a bipartite NLS is involved in nuclear translocation of lambda PKC. The KRFNRR motif, although shorter, is most similar to a type of monopartite NLSs enriched in arginine residues identified in the Tat and Rev proteins of human immunodeficiency virus-1 and the Rex protein of human T-cell leukemia virus type 1. These proteins have been demonstrated to be imported into the nucleus by importin beta  in an importin alpha -independent manner (66, 67).

We have found that in contrast to wild-type lambda PKC that mainly localized to the cytoplasm, two different point mutations in the catalytic domain led to nuclear accumulation of full-length lambda PKC. Nuclear accumulation also occurred with deletion mutants lacking either the catalytic domain or the 140 N-terminal amino acids including the pseudosubstrate sequence. Importantly, the A129E point mutation in the pseudosubstrate sequence, which disrupts the interaction between this autoinhibitory sequence and the substrate interaction site in the catalytic domain, also led to nuclear accumulation of full-length lambda PKC fused to GFP. The deletion mutant is exclusively nuclear, whereas the point mutant is found also in the cytoplasm. This difference in the extent of relocalization relative to the wild-type enzyme is consistent with previous findings showing that regions of the regulatory domain of PKCs outside the pseudosubstrate sequence contribute to autoinhibition (68). We therefore suggest that intramolecular interactions between the catalytic domain and the N-terminal part of the protein regulate the conformation of the protein in such a way that the accessibility of the NLS, the NES, or both signaling sequences is affected. Such a model of regulation has been suggested for the serine/threonine kinase MAPKAP kinase-2 (44). According to this model, an NLS within MAPKAP kinase-2 is exposed both in the inactive and active enzyme. In the inactive enzyme an NES motif is masked due to intramolecular interaction between an autoinhibitory region and the catalytic domain. Consequently, inactive MAPKAP kinase-2 is localized to the nucleus. However, upon phosphorylation and activation by p38, the intramolecular interaction is relieved leading to unmasking of the NES. When both the NLS and NES are exposed, the protein is exported from the nucleus more efficiently than it is imported (44). For lambda PKC we suggest that it is primarily the exposure of the NLS that is regulated through intramolecular interactions between the catalytic domain and the N-terminal region. An interaction between the pseudosubstrate sequence in the N-terminal parts of the PKC enzymes and the substrate interaction site in the catalytic domain is well documented (69). To understand fully the intramolecular interactions regulating activity and subcellular localization, it will be necessary to determine the three-dimensional structure of both wild-type and mutant lambda PKC.

As mentioned in the Introduction, nuclear localization of both lambda PKC and zeta PKC has been reported (8, 33, 35). Recently, it was shown that translocation of zeta PKC to the nucleus following NGF stimulation of PC12 cells probably depends on nuclear PI 3-kinase activity (34). Interestingly, evidence for the existence of nuclear PI 3-kinase activity has been provided (70-72). It has earlier been proposed that conventional PKC isoforms may continuously shuttle in and out of the nucleus and become "trapped" in the nucleus by an increase in the nuclear level of diacylglycerol (73). In line with this hypothesis, Neri et al. (34) suggest that zeta PKC is similarly trapped following an increase in nuclear phosphatidylinositol 3,4,5-trisphosphate. Due to their large size a functional NLS is required for nuclear import of aPKCs. We find that the zinc finger domain contains a functional, although atypical, basic NLS. This signal functions independently of a structurally intact zinc finger in the context of a GFP fusion. However, we cannot rule out the possibility that in the context of the full-length protein an intact zinc finger is required for nuclear accumulation. This is particularly the case since the two Arg residues we mutated to Glu resulting in loss of nuclear import may also be involved in the binding of phosphatidylinositol 3,4,5-trisphosphate. Thus, a conformational change may expose the NLS which then enables nuclear import. Subsequently, the protein may become trapped in the nucleus due to binding of nuclear phosphatidylinositol 3,4,5-trisphosphate by the zinc finger.

We find that zeta PKC is much more inefficiently imported into the nucleus than lambda PKC upon inhibition of nuclear export. This is in apparent conflict with the work showing rapid nuclear translocation of zeta PKC following NGF treatment of PC12 cells. However, it is possible that nuclear translocation of zeta PKC is more tightly regulated than that of lambda PKC perhaps via posttranslational modifications induced by specific stimuli. Another possibility is that both Neri et al. (34) and Wooten et al. (35) are actually looking more at lambda PKC than zeta PKC since the antibodies they used actually recognize both isoforms of aPKCs. We find that PC12 cells express lambda PKC using a specific monoclonal antibody recognizing only lambda PKC. However, a similar antibody recognizing only zeta PKC is not available.

In a recent study Sanchez et al. (57) reported that lambda PKC colocalized with a putative anchoring protein called p62 into punctate, vesicle-like structures in the cytoplasm corresponding to late endosomes. The concept of p62 serving as an anchoring protein, or perhaps more precisely a scaffolding protein, for aPKCs is very interesting since p62 also seems to be involved in recruiting other proteins into complexes harboring aPKCs (74-76). We have found that, when overexpressed, p62 is able to redistribute kinase-defective lambda PKC from the nucleus to the cytoplasm and that this ability is dependent on a direct interaction between these two proteins.2 Thus, it is clear that in addition to regulation of subcellular localization by conformational changes affecting NLS and NES function, the localization of aPKCs is also being regulated by proteins with scaffolding functions such as p62.

    ACKNOWLEDGEMENTS

We are grateful to M. Yoshida for the generous gift of leptomycin B and to J. Moscat for pcDNA3-HA and pHA-zeta . We thank T. Lamark for helpful discussions.

    FOOTNOTES

* This work was supported by grants from the Norwegian Cancer Society, the Norwegian Research Council, the Aakre Foundation, and the Blix Foundation (to T. J.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Fellow of the Norwegian Cancer Society.

§ To whom correspondence should be addressed: Dept. of Biochemistry, Institute of Medical Biology, University of Tromsø, 9037 Tromsø, Norway. Tel.: 47-776-44720; Fax: 47-776-45350; E-mail: terjej@fagmed.uit.no.

Published, JBC Papers in Press, December 13, 2000, DOI 10.1074/jbc.M010356200

2 M. Perander, G. Bjørkøy, T. Lamark, and T. Johansen, manuscript in preparation.

    ABBREVIATIONS

The abbreviations used are: PKC, protein kinase C; aPKC, atypical protein kinase C; GFP, green fluorescent protein; LMB, leptomycin B; NES, nuclear export signal; NLS, nuclear localization signal; PCR, polymerase chain reaction; DAG, diacylglycerol; PI 3-kinase, phosphatidylinositol 3-kinase; NGF, nerve growth factor; DAPI, 4,6-diamidino-2-phenylindole; HA, hemagglutinin; nt, nucleotide; MAPKAP-kinase 2, mitogen-activated protein kinase-activated protein kinase-2.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Ron, D., and Kazanietz, M. G. (1999) FASEB J. 13, 1658-1676[Abstract/Free Full Text]
2. Nishizuka, Y. (1995) FASEB J. 9, 484-496[Abstract/Free Full Text]
3. Mellor, H., and Parker, P. J. (1998) Biochem. J. 332, 281-292[Medline] [Order article via Infotrieve]
4. Ono, Y., Fujii, T., Ogita, K., Kikkawa, U., Igarashi, K., and Nishizuka, Y. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 3099-3103[Abstract]
5. Akimoto, K., Mizuno, K., Osada, S., Hirai, S., Tanuma, S., Suzuki, K., and Ohno, S. (1994) J. Biol. Chem. 269, 12677-12683[Abstract/Free Full Text]
6. Muller, G., Ayoub, M., Storz, P., Rennecke, J., Fabbro, D., and Pfizenmaier, K. (1995) EMBO J. 14, 1961-1969[Abstract]
7. Lozano, J., Berra, E., Municio, M. M., Diaz-Meco, M. T., Dominguez, I., Sanz, L., and Moscat, J. (1994) J. Biol. Chem. 269, 19200-19202[Abstract/Free Full Text]
8. Akimoto, K., Takahashi, R., Moriya, S., Nishioka, N., Takayanagi, J., Kimura, K., Fukui, Y., Osada, S.-I., Mizuno, K., Hirai, S.-I., Kazlauskas, A., and Ohno, S. (1996) EMBO J. 15, 788-798[Abstract]
9. Nakanishi, H., Brewe, K. A., and Exton, J. H. (1993) J. Biol. Chem. 268, 13-16[Abstract/Free Full Text]
10. Standaert, M. L., Galloway, L., Karnam, P., Bandyopadhyay, G., Moscat, J., and Farese, R. V. (1997) J. Biol. Chem. 272, 30075-30082[Abstract/Free Full Text]
11. Sontag, E., Sontag, J. M., and Garcia, A. (1997) EMBO J. 16, 5662-5671[Abstract/Free Full Text]
12. Herrera Velit, P., Knutson, K. L., and Reiner, N. E. (1997) J. Biol. Chem. 272, 16445-16452[Abstract/Free Full Text]
13. Chou, M.-M., Hou, W., Johnson, J., Graham, L.-K., Lee, M.-H., Chen, C.-S., Newton, A.-C., Schaffhausen, B.-S., and Toker, A. (1998) Curr. Biol. 8, 1069-1077[Medline] [Order article via Infotrieve]
14. Takeda, H., Matozaki, T., Takada, T., Noguchi, T., Yamao, T., Tsuda, M., Ochi, F., Fukunaga, K., Inagaki, K., and Kasuga, M. (1999) EMBO J. 18, 386-395[Abstract/Free Full Text]
15. Dominguez, I., Diaz-Meco, M. T., Municio, M. M., Berra, E., García de Herreros, A., Cornet, M. E., Sanz, L., and Moscat, J. (1992) Mol. Cell. Biol. 12, 3776-3783[Abstract]
16. Berra, E., Diaz-Meco, M. T., Dominguez, I., Municio, M. M., Sanz, L., Lozano, J., Chapkin, R. S., and Moscat, J. (1993) Cell 74, 555-563[Medline] [Order article via Infotrieve]
17. Coleman, E. S., and Wooten, M. W. (1994) J. Mol. Neurosci. 5, 39-57[Medline] [Order article via Infotrieve]
18. Wooten, M. W., Zhou, G., Seibenhener, M. L., and Coleman, E. S. (1994) Cell Growth Differ. 5, 395-403[Abstract]
19. Liu, Q., Ning, W., Dantzer, R., Freund, G. G., and Kelley, K. W. (1998) J. Immunol. 160, 1393-1401[Abstract/Free Full Text]
20. Brazil, D. P., and Hemmings, B. (2000) Curr. Biol. 10, 592-594
21. Mendez, R., Kollmorgen, G., White, M. F., and Rhoads, R. E. (1997) Mol. Cell. Biol. 17, 5184-5192[Abstract]
22. Bandyopadhyay, G., Standaert, M. L., Kikkawa, U., Ono, Y., Moscat, J., and Farese, R. V. (1999) Biochem. J. 337, 461-470[CrossRef][Medline] [Order article via Infotrieve]
23. Standaert, M. L., Bandyopadhyay, G., Sajan, M. P., Cong, L., Quon, M. J., and Farese, R. V. (1999) J. Biol. Chem. 274, 14074-14078[Abstract/Free Full Text]
24. Kotani, K., Ogawa, W., Matsumoto, M., Kitamura, T., Sakaue, H., Hino, Y., Miyake, K., Sano, W., Akimoto, K., Ohno, S., and Kasuga, M. (1998) Mol. Cell. Biol. 18, 6971-6982[Abstract/Free Full Text]
25. Xu, J., Zutter, M. M., Santoro, S. A., and Clark, R. A. (1996) J. Cell Biol. 134, 1301-1311[Abstract]
26. Diaz-Meco, M. T., Municio, M. M., Frutos, S., Sanchez, P., Lozano, J., Sanz, L., and Moscat, J. (1996) Cell 86, 777-786[Medline] [Order article via Infotrieve]
27. Berra, E., Municio, M. M., Sanz, L., Frutos, S., Diaz Meco, M. T., and Moscat, J. (1997) Mol. Cell. Biol. 17, 4346-4354[Abstract]
28. Murray, N. R., and Fields, A. P. (1997) J. Biol. Chem. 272, 27521-27524[Abstract/Free Full Text]
29. Diaz-Meco, M. T., Lallena, M. J., Monjas, A., Frutos, S., and Moscat, J. (1999) J. Biol. Chem. 274, 19606-19612[Abstract/Free Full Text]
30. Frutos, S., Moscat, J., and Diaz-Meco, M. T. (1999) J. Biol. Chem. 274, 10765-10770[Abstract/Free Full Text]
31. Municio, M. M., Lazano, J., Sancez, P., Moscat, J., and Diaz-Meco, M. T. (1995) J. Biol. Chem. 270, 15884-15891[Abstract/Free Full Text]
32. Pal, S., Claffey, K. P., Cohen, H. T., and Mukhopadhyay, D. (1998) J. Biol. Chem. 273, 26277-26280[Abstract/Free Full Text]
33. Zhou, G., Seibenhener, M. L., and Wooten, M. W. (1997) J. Biol. Chem. 272, 31130-31137[Abstract/Free Full Text]
34. Neri, L. M., Martelli, A. M., Borgatti, P., Colamussi, M. L., Marchisio, M., and Capitani, S. (1999) FASEB J. 13, 2299-2310[Abstract/Free Full Text]
35. Wooten, M. W., Zhou, G., Wooten, M. C., and Seibenhener, M. L. (1997) J. Neurosci. Res. 49, 393-403[CrossRef][Medline] [Order article via Infotrieve]
36. Dingwall, C., and Laskey, R. A. (1991) Trends Biochem. Sci. 16, 478-481[CrossRef][Medline] [Order article via Infotrieve]
37. Conti, E., Uy, M., Leighton, L., Blobel, G., and Kuriyan, J. (1998) Cell 94, 193-204[Medline] [Order article via Infotrieve]
38. Gorlich, D. (1998) EMBO J. 17, 2721-2727[Free Full Text]
39. Nigg, E. A. (1997) Nature 386, 779-787[CrossRef][Medline] [Order article via Infotrieve]
40. Adam, S. A. (1999) Curr. Opin. Cell Biol. 11, 402-406[CrossRef][Medline] [Order article via Infotrieve]
41. Fischer, U., Huber, J., Boelens, W. C., Mattaj, I. W., and Luhrmann, R. (1995) Cell 82, 475-483[Medline] [Order article via Infotrieve]
42. Wen, W., Meinkoth, J. L., Tsien, R. Y., and Taylor, S. S. (1995) Cell 82, 463-473[Medline] [Order article via Infotrieve]
43. Fukuda, M., Gotoh, I., Gotoh, Y., and Nishida, E. (1996) J. Biol. Chem. 271, 20024-20028[Abstract/Free Full Text]
44. Engel, K., Kotlyarov, A., and Gaestel, M. (1998) EMBO J. 17, 3363-3371[Abstract/Free Full Text]
45. Toyoshima, F., Moriguchi, T., Wada, A., Fukuda, M., and Nishida, E. (1998) EMBO J. 17, 2728-2735[Abstract/Free Full Text]
46. Yamaga, M., Fujii, M., Kamata, H., Hirata, H., and Yagisawa, H. (1999) J. Biol. Chem. 274, 28537-28541[Abstract/Free Full Text]
47. Fukuda, M., Asano, S., Nakamura, T., Adachi, M., Yoshida, M., Yanagida, M., and Nishida, E. (1997) Nature 390, 308-311[CrossRef][Medline] [Order article via Infotrieve]
48. Fornerod, M., Ohno, M., Yoshida, M., and Mattaj, I. W. (1997) Cell 90, 1051-1060[Medline] [Order article via Infotrieve]
49. Stade, K., Ford, C. S., Guthrie, C., and Weis, K. (1997) Cell 90, 1041-1050[Medline] [Order article via Infotrieve]
50. Ossareh-Nazari, B., Bachelerie, F., and Dargemont, C. (1997) Science 278, 141-144[Abstract/Free Full Text]
51. Kudo, N., Matsumori, N., Taoka, H., Fujiwara, D., Schreiner, E. P., Wolff, B., Yoshida, M., and Horinouchi, S. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 9112-9117[Abstract/Free Full Text]
52. Selbie, L. A., Schitz-Peiffer, C., Sheng, Y., and Biden, T. J. (1993) J. Biol. Chem. 268, 24296-24302[Abstract/Free Full Text]
53. Nead, M. A., Baglia, L. A., Antinore, M. J., Ludlow, J. W., and McCance, D. J. (1998) EMBO J. 17, 2342-2352[Abstract/Free Full Text]
54. Orr, J. W., and Newton, A. C. (1994) J. Biol. Chem. 269, 27715-27718[Abstract/Free Full Text]
55. Le Good, J. A., Ziegler, W. H., Parekh, D. B., Alessi, D. R., Cohen, P., and Parker, P. J. (1998) Science 281, 2042-2045[Abstract/Free Full Text]
56. Überall, F., Giselbrecht, S., Hellbert, K., Fresser, F., Bauer, B., Gschwendt, M., Grunicke, H. H., and Baier, G. (1997) J. Biol. Chem. 272, 4072-4078[Abstract/Free Full Text]
57. Sanchez, P., De Carcer, G., Sandoval, I. V., Moscat, J., and Diaz Meco, M. T. (1998) Mol. Cell. Biol. 18, 3069-3080[Abstract/Free Full Text]
58. Bastiaens, P. I., and Jovin, T. M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 8407-8412[Abstract/Free Full Text]
59. Greif, H., Ben-Chaim, J., Shimon, T., Bechor, E., Eldar, H., and Livneh, E. (1992) Mol. Cell. Biol. 12, 1304-1311[Abstract]
60. Hocevar, B. A., and Fields, A. P. (1991) J. Biol. Chem. 266, 28-33[Abstract/Free Full Text]
61. James, G., and Olson, E. (1992) J. Cell Biol. 116, 863-874[Abstract]
62. Leach, K. L., Ruff, V. A., Jarpe, M. B., Adams, L. D., Fabbro, D., and Raben, D. M. (1992) J. Biol. Chem. 267, 21816-21822[Abstract/Free Full Text]
63. Rosenberger, U., Shakibaei, M., and Buchner, K. (1995) Biochem. J. 305, 269-275[Medline] [Order article via Infotrieve]
64. Schmalz, D., Hucho, F., and Buchner, K. (1998) J. Cell Sci. 111, 1823-1830[Abstract/Free Full Text]
65. Oancea, E., Teruel, M. N., Quest, A. F., and Meyer, T. (1998) J. Cell Biol. 140, 485-498[Abstract/Free Full Text]
66. Palmeri, D., and Malim, M. H. (1999) Mol. Cell. Biol. 19, 1218-1225[Abstract/Free Full Text]
67. Truant, R., and Cullen, B. R. (1999) Mol. Cell. Biol. 19, 1210-1217[Abstract/Free Full Text]
68. Parissenti, A. M., Kirwan, A. F., Kim, S. A., Colantonio, C. M., and Schimmer, B. P. (1998) J. Biol. Chem. 273, 8940-8945[Abstract/Free Full Text]
69. Orr, J. W., and Newton, A. C. (1994) J. Biol. Chem. 269, 8383-8387[Abstract/Free Full Text]
70. Metjian, A., Roll, R. L., Ma, A. D., and Abrams, C. S. (1999) J. Biol. Chem. 274, 27943-27947[Abstract/Free Full Text]
71. Neri, L. M., Milani, D., Bertolaso, L., Stroscio, M., Bertagnolo, V., and Capitani, S. (1994) Cell. Mol. Biol. 40, 619-626
72. Tanaka, K., Horiguchi, K., Yoshida, T., Takeda, M., Fujisawa, H., Takeuchi, K., Umeda, M., Kato, S., Ihara, S., Nagata, S., and Fukui, Y. (1999) J. Biol. Chem. 274, 3919-3922[Abstract/Free Full Text]
73. Divecha, N., Banfic, H., and Irvine, R. F. (1993) Cell 74, 405-407[Medline] [Order article via Infotrieve]
74. Gong, J., Xu, J., Bezanilla, M., van Huizen, R., Derin, R., and Li, M. (1999) Science 285, 1565-1569[Abstract/Free Full Text]
75. Sanz, L., Sanchez, P., Lallena, M. J., Diaz-Meco, M. T., and Moscat, J. (1999) EMBO J. 18, 3044-3053[Abstract/Free Full Text]
76. Moscat, J., and Diaz-Meco, T. (2000) EMBO Rep. 1, 399-403[Abstract/Free Full Text]
77. Zhang, G., Kazanietz, M. G., Blumberg, P. M., and Hurley, J. H. (1995) Cell 81, 917-924[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.